STEMCELL Technologies and Immudex Launch New Protocol for Rapid and Gentle Enrichment of Antigen-Specific T Cells
Vancouver, Canada & Copenhagen, Denmark — November 18, 2025 — STEMCELL Technologies and Immudex are proud to announce the launch of a new protocol that combines the power of the EasySep™ Release positive selection platform with Immudex’s Dextramer® reagents, enabling researchers to isolate rare antigen-specific T cells, MAIT cells and iNKT cells with unprecedented ease, speed, and purity.
This innovative method offers a compelling alternative to traditional fluorescence-activated cell sorting (FACS), which is often costly, time-consuming, and technically demanding.
The new EasySep™ Release Dextramer® protocol is:
EASY & EFFICIENT
Isolate antigen-specific T cells in as little as 45 minutes with minimal hands-on time. The streamlined workflow is ideal for labs seeking high-throughput, reproducible results without the need for sterile cell sorting equipment.
PARTICLE-FREE & GENTLE
The protocol enables high-purity, particle-free enrichment of target T cells, making them immediately suitable for downstream applications. The gentle enrichment process is designed to avoid stress to the cells, perturbations of phenotype and minimize loss of fragile cells.
COMPATIBLE
Enriched cells are ideal for downstream applications including flow cytometry, functional assays, single-cell analysis, and TCR discovery workflows. Post-enrichment, Dextramer® reagents can be used to verify the percentage of target cells, adding a layer of confidence and precision to your analysis.
This joint protocol empowers immunology and cell therapy researchers to accelerate discovery while maintaining the highest standards of cell quality and specificity.
“This collaboration brings together two best-in-class technologies to streamline a complex and critical step in immunology research, allowing scientists to optimize their time while yielding consistent results,” said Dr. Sharon Louis, Senior Vice President, Research and Development, STEMCELL. “As Scientists Helping Scientists, we are proud to release this new protocol in partnership with Immudex to help researchers gain efficiencies without compromising quality so that they can make discoveries with greater acceleration and confidence.”
“By pairing Immudex’s Dextramer® reagents with STEMCELL’s EasySep™ Release system, researchers gain both precision and flexibility,” added Henrik Pfundheller, CCO of Immudex.
Further Information
EasySep™ Release Human PE Positive Selection Kit
Dextramer® reagents for isolation of antigen-specific immune cells
About STEMCELL Technologies
STEMCELL Technologies supports life sciences research with more than 2,500 specialized reagents, tools, and services. STEMCELL offers high-quality cell culture media, cell separation technologies, instruments, accessory products, educational resources, and contract assay services that are used by scientists performing stem cell, immunology, cancer, regenerative medicine, and cellular therapy research globally.
About Immudex
Immudex ApS is a pioneering life science company and the trusted partner of scientists worldwide spearheading the global adoption of precision cellular immune monitoring. Immudex’s mission is to help researchers and clinicians unravel the complexity of the immune system, enabling the development of more effective immune-based therapeutics and diagnostics.
Immudex operates globally, with headquarters in Copenhagen, Denmark, and North American operations based in Philadelphia, Pennsylvania. Immudex’s Dextramer® technology is superior for the detection of antigen-specific immune cells, including rare and low-affinity cells. Immudex offers a broad product portfolio that allows scientists to investigate diverse types of immune cells, including T cells, non-conventional T cells and B cells, with reagents tailored to specific applications. Immudex’s products are compatible with multiple platforms from flow cytometry to next generation sequencing and single-cell multi-omics.
In addition to Dextramer® reagents for basic research, Immudex also provides Dextramer® (GMP) products and Dextramer® CMV Kits (IVD) manufactured in ISO 13485:2016-certified facilities, according to the requirements of FDA QSR 21 CFR 820. Immudex’s products enable scientists to get the full picture of the immune response, supporting ground-breaking advances within immuno-oncology, transplantation, autoimmune and infectious diseases. Find out more at www.immudex.com.
Trademark Notice
EasySep™ is a trademark of STEMCELL Technologies.
Dextramer® is a registered trademark of Immudex ApS.